Status:

COMPLETED

Comparing the Effectiveness of a Treat-to-target (T2T) Disease Management Strategy vs. Routine Care (RC) in Adult Patients With Moderate to Severe Rheumatoid Arthritis (RA) Treated With Subcutaneous Abatacept (Orencia - SC)

Lead Sponsor:

Bristol-Myers Squibb

Conditions:

Rheumatoid Arthritis

Eligibility:

All Genders

18+ years

Brief Summary

This is a 12 month prospective, multicenter, post-marketing, observational study to compare the effectiveness of a treat-to-target (T2T) disease management strategy vs. routine care (RC) in adult pati...

Eligibility Criteria

Inclusion

  • 18 years of age or older.
  • Active moderate to severe RA, defined as CDAI \> 10.
  • The treating physician has made the decision to initiate treatment with SC abatacept in accordance with the Canadian product monograph.
  • Patient has provided a written informed consent and is able to complete the survey requirements.
  • Patient fulfills the reimbursement criteria for treatment with SC abatacept under provincial or private health insurance reimbursement coverage.

Exclusion

  • Has received abatacept (SC or IV) prior to the enrolment visit.
  • Has failed more than one prior biologic DMARD therapy
  • Has a history of autoimmune disease or of any joint inflammatory disease other than RA with the exception of concomitant secondary Sjogren's syndrome.
  • Is participating in an ongoing clinical trial and/or has received treatment with an investigational agent within 4 weeks before starting treatment with SC abatacept.
  • Is participating in another industry-sponsored observational study.
  • Patients participating to non-industry related registries or other data collection studies can be included
  • Presence of any condition that, in the opinion of the treating physician, prohibits the patient from participating in the study or obscures the assessment of RA treatment.

Key Trial Info

Start Date :

October 31 2011

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

October 31 2018

Estimated Enrollment :

281 Patients enrolled

Trial Details

Trial ID

NCT03274141

Start Date

October 31 2011

End Date

October 31 2018

Last Update

January 30 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Local Institution

Westmount, Quebec, Canada, H3Z 1R7